Skip to main content

Table 2 Clinical outcome

From: Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis

 

Population (N = 291)

Relapses during study (n = 267)

 

   No relapse

180 (67.4%)

   1 relapse

61 (22.8%)

   2 relapses

12 (4.5%)

   3 relapses

8 (3.0%)

   4–5 relapses

3 (1.1%)

Mean EDSS scores (n = 235)

 

   Baseline

2.58 ± 1.45

   Study end

2.45 ± 1.52

   Change from baseline

-0.13 ± 0.73*

  1. Data are presented as number of patients (%) for relapses and as mean ± SD for Expanded Disability Status Scale (EDSS) scores. The asterisk indicates a significant change from baseline (p < 0.05; Wilcoxon signed rank test).
Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us